New Hybrid Mpox Strain Discovered in England Health Officials Issue Urgent Alert

Health officials in England have announced the discovery of a new hybrid strain of mpox, prompting urgent alerts for vaccination and vigilance. The UK Health Security Agency (UKHSA) reported this finding on December 8, revealing that the strain was detected in an individual who had recently traveled from Asia.

Details of the New Hybrid Mpox Strain

This new variant is identified as a recombinant strain, comprising genetic material from two distinct mpox clades currently circulating worldwide. Mpox, formerly known as monkeypox, belongs to the same virus family as smallpox and typically emerges in regions of central and east Africa.

The occurrence of the clade Ib variant outside of its endemic areas, such as Europe and North America, has raised significant concern. In August 2024, the World Health Organization (WHO) declared mpox a global health emergency due to the global outbreak that began in 2022, which led to an increase in cases around the world.

Characteristics of the New Strain

The UKHSA emphasized that this new strain comprises elements from both clades Ib and IIb. While the emergence of such strains is not entirely unforeseen, it highlights the virus’s potential to evolve and adapt. The agency is currently evaluating the potential implications of this discovery and whether this hybrid strain might exhibit different characteristics.

Vaccination and Public Health Advice

Dr. Katy Sinka, Head of Sexually Transmitted Infections at UKHSA, emphasized the importance of understanding the genetic evolution of mpox. Vaccination remains a crucial strategy for mitigating the risk of severe infection. The UK has implemented a routine mpox vaccination program targeting specific high-risk groups, including:

• Individuals with multiple sexual partners
• Those participating in group sex
• Visitors to sex-on-premises venues

The UKHSA reports that the mpox vaccine shows approximately 75-80% effectiveness in preventing the disease. Symptoms of mpox include:

• A painful skin rash or pus-filled lesions lasting 2 to 4 weeks
• Fever
• Headaches
• Muscle aches and back pain
• Low energy
• Swollen lymph nodes

Officials urge anyone who suspects they may have mpox to seek guidance by contacting NHS 111. Remaining alert and getting vaccinated if eligible is critical to controlling the spread of this disease.